Balyasny Asset Management
WST icon

Balyasny Asset Management’s West Pharmaceutical WST Stock Holding History

Balyasny Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Buy
45,766
+44,645
+3,983% +$13.6M 0.02% 817
2026
Q1 		$281K Sell
1,121
-54
-5% -$13.4K ﹤0.01% 2582
2025
Q4 		$323K Sell
1,175
-44,498
-97% -$12.2M ﹤0.01% 2701
2025
Q3 		$12M Buy
+45,673
New +$11.1M 0.02% 961
2025
Q1 		– Sell
-35,624
Closed -$11.7M – 3351
2024
Q4 		$11.7M Buy
+35,624
New +$11.2M 0.02% 895
2024
Q3 		– Sell
-4,148
Closed -$1.37M – 3215
2024
Q2 		$1.37M Sell
4,148
-3,034
-42% -$1.07M ﹤0.01% 1674
2024
Q1 		$2.84M Sell
7,182
-206,343
-97% -$76.3M 0.01% 1427
2023
Q4 		$75.2M Buy
213,525
+6,521
+3% +$2.31M 0.14% 173
2023
Q3 		$77.7M Buy
+207,004
New +$80.1M 0.16% 158
2023
Q1 		– Sell
-21,065
Closed -$4.96M – 3214
2022
Q4 		$4.96M Buy
+21,065
New +$4.99M 0.01% 1036
2021
Q4 		– Sell
-15,150
Closed -$6.43M – 2633
2021
Q3 		$6.43M Buy
+15,150
New +$6.39M 0.03% 736
2021
Q1 		– Sell
-28,646
Closed -$8.12M – 2115
2020
Q4 		$8.12M Sell
28,646
-20,208
-41% -$5.67M 0.05% 493
2020
Q3 		$13.4M Buy
48,854
+38,506
+372% +$10.2M 0.1% 305
2020
Q2 		$2.35M Buy
+10,348
New +$2.03M 0.02% 686
2019
Q4 		– Sell
-2,983
Closed -$423K – 1535
2019
Q3 		$423K Sell
2,983
-16,502
-85% -$2.27M ﹤0.01% 971
2019
Q2 		$2.44M Buy
+19,485
New +$2.3M 0.02% 819
2019
Q1 		– Sell
-8,305
Closed -$814K – 1692
2018
Q4 		$814K Buy
+8,305
New +$901K 0.01% 964
2018
Q2 		– Sell
-17,229
Closed -$1.52M – 2191
2018
Q1 		$1.52M Buy
17,229
+8,179
+90% +$765K 0.01% 1076
2017
Q4 		$893K Buy
9,050
+3,826
+73% +$375K ﹤0.01% 1372
2017
Q3 		$503K Sell
5,224
-3,638
-41% -$329K ﹤0.01% 1356
2017
Q2 		$838K Sell
8,862
-4,331
-33% -$398K ﹤0.01% 1150
2017
Q1 		$1.08M Buy
13,193
+6,893
+109% +$576K 0.01% 1073
2016
Q4 		$534K Buy
+6,300
New +$495K ﹤0.01% 1136

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Balyasny Asset Management's WST Position: Q2 2026 in Review

Balyasny Asset Management increased its West Pharmaceutical (WST) stake by 3,983% in Q2 2026, buying an estimated $13.6M and bringing the position to 45,766 shares worth $16.4M. The position accounts for 0.02% of the portfolio, ranked #817.

Balyasny Asset Management first reported a position in WST in Q4 2016 and has held it in 23 quarters since. The position peaked at $77.7M in Q3 2023. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Balyasny Asset Management held 45,766 shares of West Pharmaceutical worth $16.4M as of Q2 2026.
  • Balyasny Asset Management bought 44,645 West Pharmaceutical shares in Q2 2026, an estimated $13.6M.
  • West Pharmaceutical made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #817 holding.
  • Balyasny Asset Management first reported a position in West Pharmaceutical in Q4 2016 and has held it in 23 quarters since.
  • Balyasny Asset Management's West Pharmaceutical position peaked at $77.7M in Q3 2023.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.